{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:00:11Z","timestamp":1785214811000,"version":"3.55.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u03ccw Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["SUBZ.C280.26.041"],"award-info":[{"award-number":["SUBZ.C280.26.041"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Postmenopausal women commonly present with HR-positive\/HER2-negative breast cancer. Neoadjuvant endocrine therapy (NET) may facilitate breast-conserving surgery (BCS) and de-escalation of axillary surgery. This study evaluated NET efficacy in enabling surgical de-escalation in luminal breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A retrospective study included postmenopausal women (\u226549 years) with newly diagnosed, luminal breast cancer treated with NET between May 2021 and May 2024 at a single tertiary breast unit. Patients with stage IV disease or contraindications to surgery were excluded. Clinical and pathologic variables were collected from chart review. Tumor and nodal downstaging were defined by decrease of at least one level from clinical (cT or cN) to pathologic (ypT or ypN) stage. Multivariable logistic regression was used to identify predictors of downstaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 124 patients (128 tumors) were included. Mean age at diagnosis was 69 years. NET resulted in a significant reduction in tumor size (mean absolute reduction 10.93\u00a0mm; p &amp;lt; 0.0001; mean relative reduction 23.4%; p &amp;lt; 0.0001). BCS was achieved in 75.8% of cases, and NET was estimated to have avoided mastectomy in at least 27 patients. Lobular histology (OR 2.92, 95% CI 1.20\u20137.00; p = 0.017) and absence of clinical nodal involvement (OR 3.10, 95% CI 1.45\u20136.55; p = 0.003) were independently associated with T-stage downstaging.<\/jats:p>\n                    <jats:p>Regarding axillary management, 75.8% underwent sentinel lymph node biopsy and 22.7% upfront axillary lymph node dissection. Among patients initially managed with SLNB, 35% required completion ALND. Of 60 clinically node-positive (cN1) patients, 8 (12.7%) achieved ypN0 status after NET. Micrometastatic residual disease was observed in 4 additional cases (6.3% of cN1 patients).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NET effectively facilitates breast-conserving surgery in postmenopausal patients with luminal breast cancer. However, its impact on achieving nodal clearance and reducing axillary dissection remains limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1831764","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:26:12Z","timestamp":1785212772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Can neoadjuvant endocrine therapy de-escalate surgery in luminal breast cancer? A four-year retrospective study from a single referral center"],"prefix":"10.3389","volume":"16","author":[{"given":"Aleksander","family":"Skulimowski","sequence":"first","affiliation":[{"name":"Breast Unit, II Department of Surgical Oncology, Lower Silesian Center of Oncology, Pulmonology, and Hematology","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Sk\u00f3rniak","sequence":"additional","affiliation":[{"name":"Breast Unit, II Department of Surgical Oncology, Lower Silesian Center of Oncology, Pulmonology, and Hematology","place":["Wroclaw, Poland"]},{"name":"Department of Oncology, Faculty of Medicine, Wroclaw Medical University","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Michalik","sequence":"additional","affiliation":[{"name":"Breast Unit, II Department of Surgical Oncology, Lower Silesian Center of Oncology, Pulmonology, and Hematology","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ekiert","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine, Wroclaw Medical University","place":["Wroclaw, Poland"]},{"name":"Department of Oncology, Lower Silesian Center of Oncology, Pulmonology, and Hematology","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Skulimowska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Internal Medicine, Tadeusz Marciniak Lower Silesia Specialist Hospital-Centre for Medical Emergency","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kasprzak","sequence":"additional","affiliation":[{"name":"Department of Radiology, Lower Silesian Center of Oncology, Pulmonology, and Hematology","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Matkowski","sequence":"additional","affiliation":[{"name":"Breast Unit, II Department of Surgical Oncology, Lower Silesian Center of Oncology, Pulmonology, and Hematology","place":["Wroclaw, Poland"]},{"name":"Department of Oncology, Faculty of Medicine, Wroclaw Medical University","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5603\/NJO.2023.0026","article-title":"Cancer incidence and mortality in Poland in 2020","volume":"73","author":"Wojciechowska","year":"2023","journal-title":"Nowotwory J Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor\u2013positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"key":"B5","volume-title":"Cancer Stat Facts: Female Breast Cancer Subtypes","year":"2024"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13226","article-title":"Incidence trends of breast cancer molecular subtypes by age and race\/ethnicity in the US from 2010 to 2016","volume":"3","author":"Acheampong","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04245-1","article-title":"10-year survival in female breast cancer patients according to ER, PR and HER2 expression: a cancer registry population-based analysis","volume":"149","author":"Intrieri","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22643","article-title":"Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis","volume":"8","author":"De Angelis","year":"2017","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61101858","article-title":"Molecular subtypes and survival patterns in female breast cancer: insights from a 12-year cohort","volume":"61","author":"Cobec","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1895-2","article-title":"Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 trial (CALGB 150007\/150012; ACRIN 6657)","volume":"132","author":"Esserman","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000000924","article-title":"Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial","volume":"260","author":"Boughey","year":"2014","journal-title":"Ann Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1785","article-title":"Neoadjuvant chemotherapy or endocrine therapy for invasive ductal carcinoma of the breast with high hormone receptor positivity and human epidermal growth factor receptor 2 negativity","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2019.22.e35","article-title":"Potential benefits of neoadjuvant chemotherapy in clinically node-positive luminal subtype breast cancer","volume":"22","author":"Kim","year":"2019","journal-title":"J Breast Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103280","article-title":"Neoadjuvant chemotherapy in hormone receptor\u2013positive\/HER2-negative early breast cancer: when, why and what","volume":"160","author":"Torrisi","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4274\/ejbh.galenos.2021.2021-4-8","article-title":"Neo-adjuvant chemotherapy in luminal, node-positive breast cancer: characteristics, treatment and oncological outcomes: a single center\u2019s experience","volume":"17","author":"Barbieri","year":"2021","journal-title":"Eur J Breast Health"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020163","article-title":"A comprehensive analysis of neoadjuvant chemotherapy in breast cancer: adverse events, clinical response rates, and surgical and pathological outcomes\u2014Bozyaka experience","volume":"17","author":"Y\u0131lmaz","year":"2025","journal-title":"Cancers (Bsl)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00547-5","article-title":"Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study","volume":"9","author":"Jensen","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103753","article-title":"Prediction of response to neoadjuvant chemotherapy by MammaTyper\u00ae across breast cancer subtypes: a retrospective cross-sectional study","volume":"76","author":"Schettini","year":"2024","journal-title":"Breast"},{"key":"B22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13058-020-01314-6","article-title":"Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women\u2014a literature review and proposed guidelines","volume":"22","author":"Madigan","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-015-9907-1","article-title":"One-year neoadjuvant endocrine therapy in breast cancer","volume":"21","author":"Rusz","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.07.034","article-title":"Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints","volume":"24","author":"Yeo","year":"2015","journal-title":"Breast"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08888-7","article-title":"How effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery","volume":"27","author":"Montagna","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/8866756","article-title":"Neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy in node-positive HR+, HER2- breast cancer (nodal pCR and the rate of ALND): a systematic review and meta-analysis","volume":"2024","author":"Vasigh","year":"2024","journal-title":"Breast J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.46883\/ONC.2020.3410.0397","article-title":"Strategies to optimize axillary surgery in patients with breast cancer receiving neoadjuvant endocrine therapy","volume":"34","author":"Weiss","year":"2020","journal-title":"Oncol (Williston Park)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16059-1","article-title":"Nodal response and survival after neoadjuvant endocrine therapy in hormone receptor-positive breast cancer: 20-year experience from a single institution","volume":"31","author":"An","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07785-y","article-title":"Patterns of axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach","volume":"26","author":"Weiss","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29040179","article-title":"The clinical impact of neoadjuvant endocrine treatment on luminal-like breast cancers and its prognostic significance: results from a single-institution prospective cohort study","volume":"29","author":"Mart\u00ed","year":"2022","journal-title":"Curr Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09073-6","article-title":"Axillary management after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer","volume":"28","author":"Kantor","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020192534","article-title":"Axillary nodal evaluation in breast cancer: state of the art","volume":"295","author":"Chang","year":"2020","journal-title":"Radiology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.19.22022","article-title":"Imaging-based approach to axillary lymph node staging and sentinel lymph node biopsy in patients with breast cancer","volume":"214","author":"Sun","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"B36","volume-title":"Breast Cancer (Version 4.2026)","year":"2026"},{"key":"B37","volume-title":"Early and Locally Advanced Breast Cancer: Diagnosis and Management (NICE Guideline NG101)","year":"2023"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13058-020-01288-5","article-title":"Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in premenopausal patients with estrogen receptor-positive and HER2-negative, lymph node-positive breast cancer","volume":"22","author":"Kim","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1785","article-title":"Neoadjuvant chemotherapy or endocrine therapy for invasive ductal carcinoma of the breast with high hormone receptor positivity and HER2 negativity","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10459-3","article-title":"Neoadjuvant endocrine therapy as an alternative to neoadjuvant chemotherapy among hormone receptor-positive breast cancer patients: pathologic and surgical outcomes","volume":"28","author":"Cao","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102669","article-title":"Neoadjuvant therapy in hormone receptor-positive\/HER2-negative breast cancer","volume":"123","author":"Cantini","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231200457","article-title":"Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy","volume":"15","author":"Jeong","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41523-025-00772-5","article-title":"Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+\/HER2- breast cancer","volume":"11","author":"Han","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.04.010","article-title":"Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: a systematic review and meta-analysis","volume":"58","author":"Davey","year":"2021","journal-title":"Breast"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091482","article-title":"Gene expression signatures for guiding initial therapy in ER+\/HER2- early breast cancer","volume":"17","author":"Mar\u00edn-Li\u00e9bana","year":"2025","journal-title":"Cancers (Bsl)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.1038\/s41598-022-11603-z","article-title":"Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer","volume":"12","author":"Chae","year":"2022","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or combined therapy: the IMPACT trial","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013128213451","article-title":"Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds132","article-title":"Chemotherapy and hormonotherapy as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM\/2006-03 study","volume":"23","author":"Alba","year":"2012","journal-title":"Ann Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0038","article-title":"Genome-wide crosstalk between steroid receptors in breast and prostate cancers","volume":"28","author":"Paakinaho","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae109","article-title":"Sticky business: progesterone receptors mediate cancer-associated fibroblast and breast cancer cell interaction","volume":"165","author":"Brechbuhl","year":"2024","journal-title":"Endocrinology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2020.11.053","article-title":"Neoadjuvant chemotherapy for luminal A breast cancer: factors predictive of histopathologic response and oncologic outcome","volume":"222","author":"Collins","year":"2021","journal-title":"Am J Surg"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07564-9","article-title":"Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma","volume":"26","author":"Thornton","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11866-w","article-title":"Preservation of axillary lymph nodes compared with complete dissection in T1\u20132 breast cancer patients with one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial","volume":"29","author":"Tinterri","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.08.018","article-title":"Axillary surgery in node-positive breast cancer","volume":"62","author":"Maggi","year":"2022","journal-title":"Breast"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.2840","article-title":"Association of axillary dissection with systemic therapy in patients with clinically node-positive breast cancer","volume":"158","author":"Weber","year":"2023","journal-title":"JAMA Surg"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2023.08.004","article-title":"Omission of axillary dissection in node-positive breast cancer after neoadjuvant systemic therapy","volume":"292","author":"Peery","year":"2023","journal-title":"J Surg Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2026.1268","article-title":"Sentinel lymph node biopsy for patients with cN1 HR+\/HER2- breast cancer and palpable adenopathy: a nonrandomized clinical trial","volume":"161","author":"Mamtani","year":"2026","journal-title":"JAMA Surg"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15704-z","article-title":"Should palpable nodes be exclusionary in patients who are otherwise candidates for ACOSOG Z0011-type trials","volume":"31","author":"Cardarelli","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znac305","article-title":"Axillary lymph node dissection can be omitted in patients with limited clinically node-positive breast cancer: a National Cancer Database analysis","volume":"109","author":"Cocco","year":"2022","journal-title":"Br J Surg"},{"key":"B62","volume-title":"Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive\/HER2-negative breast cancer patients undergoing preoperative endocrine therapy","author":"Smith","year":"2025"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.687244","article-title":"The role of Ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B64","volume-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","year":""}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1831764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:26:14Z","timestamp":1785212774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1831764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":64,"alternative-id":["10.3389\/fonc.2026.1831764"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1831764","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1831764"}}